Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Kaposi sarcoma remains the most common malignancy among persons with HIV.

Lesions localized to the airway may cause bleeding, pain and dyspnea.

New therapeutic approaches for local disease are needed.

The purpose of this study is to compare the effectiveness of intralesional bevacizumab + HAART vs HAART alone in treating localized Kaposi´s sarcoma of the airway in patients with AIDS.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico
• Treatments: Anti-Retroviral Agents; Bevacizumab

Criteria

Inclusion Criteria:

• HIV infected

• KS of the oral cavity, pharynx and larynx, histopathologically confirmed

• HIV treatment-naïve

Exclusion Criteria:

• Airway obstructive lesions

• Actively bleeding lesions

• Tumor-associated oedema or ulceration

• Gastrointestinal KS

• KS in other nonnodal viscera